Subthreshold Laser Treatment for Reticular Pseudodrusen Secondary to Age-related Macular Degeneration
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan), Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan).
- Who it may be relevant to
- Registry conditions: Macular Degeneration, Senile, Laser Burn of Retina, Macular Degeneration Intermediate, Macular Degeneration, Dry. Basic parameters: from 55 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Italy
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
Prospective, randomized, controlled, longitudinal, interventional multicentric study involving patients with reticular pseudodrusen secondary to AMD. The objective of this study is to establish the effectiveness of subthreshold laser treatment in increase/prevent the decrease of the retinal sensibility in patients with reticular pseudodrusen, and to reduce the progression of RPD to atrophy. Approximately 50 naïve patients with reticular pseudodrusen who underwent subthreshold laser treatment in perifoveal area. These patients should be randomized in the 2 study arms of the study. Patients will be evaluated at Screening/Baseline and then revaluated and retreated at month 3, 6 and 9. At month 12, all patients will be evaluated with a full ocular examination, visual acuity measurement (VA), optical coherence tomography (OCT) with autofluorescence, OCT-angiography and microperimetry. The rationale of the study is to prevent the evolution of reticular pseudodrusen to atrophic degeneration.
Interventions
- Device Pascal Synthesis 577 sub-threshold laser (Topcon Corporation, Tokyo, Japan)
The subthreshold laser treatment will be performed using subthreshold laser Pascal Synthesis 577 on a customized macular area. - Device Pascal Synthesis 577 sham (Topcon Corporation, Tokyo, Japan)
The laser treatment will be performed without any power (only the light beam) using subthreshold laser Pascal Synthesis 577 on a customized macular area.
Primary outcome measures
- Changes in the retinal sensitivity - 12 months [Time frame: 12 months]
- Anatomical changes using structural optical coherence tomography (OCT) [Time frame: 12 months]
- Rate of Progression [Time frame: 12 months]
Secondary outcome measures (4)
- Changes in the retinal sensitivity - 6 months [Time frame: 6 months]
- Anatomical changes using fundus autofluorescence (FAF) [Time frame: 12 months]
- Genetic influence (% of AMD-associated single-nucleotide polymorphism (SNP) in treated patients) [Time frame: 12 months]
- Anatomical changes using OCT-angiography (OCT-A) [Time frame: 12 months]
Eligibility criteria
Inclusion criteria
- 50 years or older
- Presence of RPD secondary to AMD
- Best-corrected visual acuity (BCVA) between 20/20 and 20/400 inclusive
- Clear ocular media
- Ability to provide informed consent and attend all study visits
Exclusion criteria
- Presence of Geographic Atrophy (GA)
- Evidence of choroidal neovascularization in either eye
- Any prior treatment for AMD, aside from antioxidants
- Any corneal opacity, cataract formation and hemorrhage in the vitreous body, which may interfere with viewing by the laser surgeon of the target structures
- Aphakic eye with vitreous in the anterior chamber
- Neovascular Glaucoma
- Glaucoma caused by congenital angle anomalies
- Open angle of less than 90º or extensive peripheral anterior and low synechia, present circumferentially around the corner
- Significant corneal edema or reduced water clarity that obscures the view angle in detail
- Glaucoma secondary to active uveitis
- Any other ocular condition that would progress in the study period and confound visual acuity assessment
- Any ocular or systemic medication known to be toxic to the lens, retina or optic nerve Presence of idiopathic or autoimmune-associated uveitis
- Any intraocular surgery 3 months of entry
- Any prior thermal laser in the macula
- History of vitrectomy, filtering surgery, corneal transplant or retinal detachment surgery
- Previous therapeutic radiation in the ocular region in either eye
- Any treatment with an investigational agent in the previous 60 days before study entry
- Women of child-bearing potential, defined as all women less than 1 year postmenopausal or less than 6 weeks since sterilization (further definition can be found in Section 12.7) at Baseline, unless they are using highly effective methods of contraception during dosing of study treatment.
- Participation in an investigational drug, biologic, or device study within 6 Months prior to Baseline \[Note: observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Treatment
Study locations
Italy · 3 centers
- Massimo Nicolò — Genova
- Giuseppe Querques — Milan
- Mariacristina Parravano — Rome
Publications
- Querques G, Sacconi R, Gelormini F, Borrelli E, Prascina F, Zucchiatti I, Querques L, Bandello F. Subthreshold laser treatment for reticular pseudodrusen secondary to age-related macular degeneration. Sci Rep. 2021 Jan 26;11(1):2193. doi: 10.1038/s41598-021-81810-7. PMID 33500505
Identifiers
NCT: NCT04847635 · PASCAL-RPD